We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
VistaGen Therapeutics Inc | NASDAQ:VTGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.74 | 4.72 | 4.91 | 112 | 12:00:06 |
On March 7, 2018, VistaGen Therapeutics, Inc. (the "Company") announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. patent application no. 15/018,219 related to methods of treating depression with AV-101, the Company's oral new generation glutamatergic product candidate in Phase 2 development for the treatment of Major Depressive Disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.
See Exhibit List.
VistaGen Therapeutics, Inc. |
By: | /s/ Shawn K. Singh |
|
|
Name: Shawn K. Singh | |
Title: Chief Executive Officer |
Exhibit No.
|
Description
|
|
EX-99.1
|
Press release issued by VistaGen Therapeutics Inc., dated March 7, 2018.
|
1 Year VistaGen Therapeutics Chart |
1 Month VistaGen Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions